---
id: difficult-GNR-comparison_070
category: organisms
tags: [GNR, MDR, comparison, stenotrophomonas, acinetobacter, burkholderia, pseudomonas]
deck: Infectious Diseases
created: 2025-11-10
modified: 2025-11-10
---

## Difficult Gram-Negative Rods: Comparison & Management

**Q:** How do you differentiate and approach treatment for difficult multidrug-resistant Gram-negative rods (Stenotrophomonas, Acinetobacter, Burkholderia, resistant Pseudomonas)?

**A:**

**Comparison Table: Difficult GNRs**

| **Feature** | **Stenotrophomonas maltophilia** | **Acinetobacter baumannii (CRAB)** | **Burkholderia cepacia complex** | **B. pseudomallei** | **MDR Pseudomonas** |
|-------------|----------------------------------|-------------------------------------|-----------------------------------|---------------------|---------------------|
| **Primary Setting** | **Post-carbapenem ICU** | **ICU, trauma, burns** | **Cystic fibrosis** | **Endemic areas** (SE Asia) | ICU, VAP |
| **Key Risk Factor** | Carbapenem use | Prolonged ICU stay | CF, CGD | **Diabetes** | Structural lung disease |
| **Intrinsic Resistance** | **Carbapenems, polymyxins** | If CRAB: all except amp-sulbactam | **Aminoglycosides, polymyxins** | Aminoglycosides, polymyxins | Variable |
| **First-Line Rx** | **TMP-SMX** | **High-dose amp-sulbactam** | **TMP-SMX, ceftazidime** | **Ceftazidime/meropenem** | Anti-pseudomonal β-lactam |
| **Second-Line Rx** | Minocycline, levofloxacin | Colistin, cefiderocol | Meropenem, minocycline | TMP-SMX (eradication) | Ceftolozane-tazobactam, C-T, I-R |
| **Combination Rx?** | ✅ Recommended (IDSA 2024) | ✅ Required | ✅ Preferred | Intensive phase only | For severe/resistant |
| **Polymyxin Active?** | ❌ No | ✅ Yes (90-95%) | ❌ No | ❌ No | ✅ Yes |
| **Carbapenem Active?** | ❌ No (MBL) | ❌ No (if CRAB) | Variable | ✅ Yes (100%) | Variable (if CRE: No) |
| **TMP-SMX Active?** | ✅ Yes (79-96%) | ❌ No | ✅ Yes (60-90%) | ✅ Yes | ❌ No |
| **Mortality** | 20-40% (bacteremia) | 40-60% (bacteremia) | >50% (Cepacia syndrome) | 40-50% (septicemic) | 30-50% (VAP) |

---

**Key Distinguishing Features:**

**1. Stenotrophomonas maltophilia:**
- **"The post-carbapenem bug"** - emerges after carbapenem use
- **TMP-SMX drug of choice** (79-96% susceptible)
- **Minocycline = backup** (98-99% susceptible, 1.4% resistance)
- **Intrinsically resistant:** Carbapenems (MBL), polymyxins, aminoglycosides
- **IDSA 2024:** Combination therapy (TMP-SMX + minocycline OR levofloxacin)
- **Colonization common** - distinguish from true infection

**2. CRAB (Carbapenem-Resistant Acinetobacter baumannii):**
- **"The ICU survivor"** - survives weeks on dry surfaces
- **High-dose ampicillin-sulbactam (9g q8h)** + combination partner (colistin OR cefiderocol)
- **Sulbactam has intrinsic anti-Acinetobacter activity**
- **Colistin + meropenem NO longer recommended** (negative RCT data)
- **Cefiderocol promising** (100% early success in 2024 meta-analysis)
- **Environmental reservoir** - outbreak potential

**3. Burkholderia cepacia Complex:**
- **"The CF killer"** - 10-20% of CF patients
- **Cepacia syndrome:** Fulminant necrotizing pneumonia + bacteremia (>50% mortality)
- **Person-to-person transmission** (CF patients segregated)
- **B. cenocepacia** (especially genomovar III) → worst prognosis
- **First-line:** TMP-SMX + ceftazidime OR meropenem-based combination
- **Lung transplant:** B. cenocepacia = relative contraindication

**4. Burkholderia pseudomallei (Melioidosis):**
- **"The great mimicker"** - mimics TB (cavitary lung), abscesses
- **Endemic:** SE Asia (Thailand #1), Northern Australia
- **Diabetes #1 risk factor** (50% of cases)
- **Biphasic treatment essential:**
  - **Intensive:** Ceftazidime or meropenem IV (10-14 days minimum)
  - **Eradication:** TMP-SMX PO (3-6 months)
- **Swiss cheese liver/spleen** (multiple abscesses)
- **NOT person-to-person**

**5. MDR Pseudomonas aeruginosa:**
- **"The persistent opportunist"**
- Structural lung disease, bronchiectasis, CF
- **First-line:** Anti-pseudomonal β-lactam (piperacillin-tazobactam, cefepime, ceftazidime, meropenem)
- **If CRE (carbapenem-resistant):** Ceftolozane-tazobactam (C-T), ceftazidime-avibactam (CAZ-AVI), imipenem-relebactam (I-R)
- **Combination therapy** for severe/resistant (β-lactam + aminoglycoside OR fluoroquinolone)
- **Polymyxins active** (unlike Stenotrophomonas/Burkholderia)

---

**Decision Tree: Which Difficult GNR?**

**Step 1: Patient Context**
- **ICU + carbapenem exposure** → Think **Stenotrophomonas** OR **CRAB**
- **Cystic fibrosis** → Think **B. cepacia complex** OR **MDR Pseudomonas**
- **Travel to SE Asia + diabetes** → Think **B. pseudomallei**
- **Burn/trauma ICU** → Think **CRAB**

**Step 2: Microbiology Clues**
- **Oxidase-positive** → Pseudomonas, Burkholderia (NOT Stenotrophomonas, Acinetobacter)
- **Oxidase-negative** → Stenotrophomonas, Acinetobacter
- **Lavender-green pigment** → Stenotrophomonas
- **Bipolar "safety pin" staining** → B. pseudomallei (Wayson stain)

**Step 3: Resistance Pattern**
- **Resistant to carbapenems + polymyxins** → **Stenotrophomonas** OR **Burkholderia**
- **Resistant to carbapenems, SUSCEPTIBLE to polymyxins** → **CRAB** OR **CRE Pseudomonas**
- **Susceptible to ceftazidime, TMP-SMX** → **B. pseudomallei** (if endemic area) OR **B. cepacia** (if CF)

---

**Treatment Approach by Organism:**

**If Stenotrophomonas:**
1. **TMP-SMX** 5 mg/kg (TMP) IV q6-8h
2. PLUS **minocycline** 100 mg IV q12h OR **levofloxacin** 750 mg IV daily
3. Duration: 7-14 days (pneumonia), 14 days (bacteremia)

**If CRAB:**
1. **High-dose ampicillin-sulbactam** 9g (amp) IV q8h (extended infusion)
2. PLUS **colistin** (loading 300 mg, then 150 mg q12h) OR **cefiderocol** 2g IV q8h
3. Duration: 7-14 days (pneumonia), 14 days (bacteremia)

**If B. cepacia Complex:**
1. **TMP-SMX** 5 mg/kg (TMP) IV q6-8h PLUS **ceftazidime** 2g IV q8h
2. OR **Meropenem** 1-2g IV q8h PLUS **minocycline** 100 mg IV q12h
3. Duration: 14-21 days (CF exacerbation)

**If B. pseudomallei (Melioidosis):**
1. **Intensive phase:** **Ceftazidime** 2g IV q6-8h OR **meropenem** 1g IV q8h (10-14 days minimum)
2. **Eradication phase:** **TMP-SMX** 8-10 mg/kg/day (TMP) PO divided BID (3-6 months)

**If MDR Pseudomonas:**
1. **Ceftolozane-tazobactam** 3g IV q8h OR **ceftazidime-avibactam** 2.5g IV q8h
2. ± **Aminoglycoside** OR **fluoroquinolone** (for severe/resistant)
3. Duration: 7-14 days (pneumonia), 14 days (bacteremia)

---

**Common Pitfalls:**

**❌ Mistake: Using carbapenems for Stenotrophomonas**
- Stenotrophomonas has MBL (L1) → intrinsically resistant
- Use **TMP-SMX**, NOT meropenem

**❌ Mistake: Using polymyxins for Stenotrophomonas or Burkholderia**
- Both intrinsically resistant to polymyxins
- Colistin will NOT work

**❌ Mistake: Using aminoglycosides for Stenotrophomonas or Burkholderia**
- Intrinsically resistant (efflux, impermeability)
- Gentamicin/tobramycin/amikacin will NOT work

**❌ Mistake: Monotherapy for Stenotrophomonas or CRAB**
- IDSA 2024: Combination therapy recommended
- Prevents resistance emergence, improves outcomes

**❌ Mistake: Short eradication phase for melioidosis**
- Minimum **3 months** TMP-SMX (relapse rate 20-30% if <3 months)
- Complicated cases: 6 months

**❌ Mistake: Using colistin + meropenem for CRAB**
- IDSA 2024: NO longer recommended (negative RCT data)
- Use high-dose amp-sulbactam + colistin OR cefiderocol instead

---

**Mnemonic: "Difficult GNRs = Don't Give carbaNeMs to Stenotrophomonas"**
- **S**tenotrophomonas: TMP-SMX + minocycline
- **C**RAB: Amp-sulbactam (high-dose) + colistin/cefiderocol
- **B**urkholderia cepacia: TMP-SMX + ceftazidime
- **M**elioidosis: Biphasic (ceftazidime → TMP-SMX)

**Mnemonic: "Polymyxin works for CRAB and Pseudomonas, NOT Stenotrophomonas or Burkholderia"**
- **C**RAB: ✅ Colistin active
- **P**seudomonas: ✅ Colistin active
- **S**tenotrophomonas: ❌ Intrinsic resistance
- **B**urkholderia: ❌ Intrinsic resistance

**Clinical Pearls:**
- **Stenotrophomonas = TMP-SMX** (first-line), minocycline (backup with 1.4% resistance)
- **CRAB = High-dose amp-sulbactam** (sulbactam is the active component)
- **B. cepacia = CF pathogen** (person-to-person transmission, Cepacia syndrome)
- **Melioidosis = biphasic treatment** (ceftazidime/meropenem → TMP-SMX 3-6 months)
- **All require combination therapy** (except possibly melioidosis eradication phase)
- **Polymyxins DON'T work** for Stenotrophomonas or Burkholderia
- **Carbapenems DON'T work** for Stenotrophomonas or CRAB
- **IDSA 2024:** Combination therapy preferred for Stenotrophomonas and CRAB
- **Remove source** (catheters, drains) whenever possible
- **Distinguish colonization from infection** (especially Stenotrophomonas)

**Media:** None

**Sources:** [IDSA 2024 - AMR guidance], Session 5 cards 066-069
